94 related articles for article (PubMed ID: 11272103)
1. Graves' disease after 131I therapy for toxic nodule.
Soule J; Mayfield R
Thyroid; 2001 Jan; 11(1):91-2. PubMed ID: 11272103
[No Abstract] [Full Text] [Related]
2. [Thyroid nodule after radioiodine (131I) therapy for Graves' disease].
Kaise K; Saito S; Sakurada T; Kaise N; Yoshida K; Yamamoto M; Fukasawa H; Nomura T; Suzuki M; Itagaki H
Kaku Igaku; 1984 Mar; 21(3):215-9. PubMed ID: 6547987
[No Abstract] [Full Text] [Related]
3. Thyrotropin receptor antibodies and Graves' disease, a side-effect of 131I treatment in patients with nontoxic goiter.
Nygaard B; Knudsen JH; Hegedüs L; Scient AV; Hansen JE
J Clin Endocrinol Metab; 1997 Sep; 82(9):2926-30. PubMed ID: 9284721
[TBL] [Abstract][Full Text] [Related]
4. [Serum free thyroxine after 131I therapy for Graves' disease (author's transl)].
Saito S; Sakurada T; Fukazawa H; Yoshida K; Kaise N; Kitaoka H; Yamamoto M; Kaise K
Kaku Igaku; 1981 Dec; 18(10):1421-4. PubMed ID: 6896222
[No Abstract] [Full Text] [Related]
5. Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves' disease and toxic multinodular goiter.
Gedik O; Ozdemir T; Akalin S
Isr J Med Sci; 1991 Jul; 27(7):361-4. PubMed ID: 1712765
[TBL] [Abstract][Full Text] [Related]
6. An uncommon case of Marine-Lenhart syndrome.
Giuffrida G; Giovinazzo S; Certo R; Vicchio TM; Baldari S; Campennì A; Ruggeri RM
Arq Bras Endocrinol Metabol; 2014 Jun; 58(4):398-401. PubMed ID: 24936736
[TBL] [Abstract][Full Text] [Related]
7. A patient with Graves' disease and three types of thyroid carcinoma.
Nunes Vdos S; Tagliarini JV; Marques ME; de Godoi JA; Mazeto GM
Thyroid; 2010 May; 20(5):573-4. PubMed ID: 20450435
[No Abstract] [Full Text] [Related]
8. Thyrotropin-releasing hormone (a test to diagnose Graves' ophthalmopathy).
Hyman BN; Johnson PC
Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol; 1975; 79(3 Pt 2):OP524-8. PubMed ID: 50663
[No Abstract] [Full Text] [Related]
9. Transition of nodular toxic goiter to autoimmune hyperthyroidism triggered by 131I therapy.
Nygaard B; Faber J; Veje A; Hegedüs L; Hansen JM
Thyroid; 1999 May; 9(5):477-81. PubMed ID: 10365679
[TBL] [Abstract][Full Text] [Related]
10. Relapse of Graves' disease 23 years after treatment with radioactive iodine (131I).
Hegele RA; Volpé R
J Clin Lab Immunol; 1985 Oct; 18(2):103-5. PubMed ID: 3841162
[TBL] [Abstract][Full Text] [Related]
11. Vocal cord paralysis after 131I therapy for solitary toxic nodule.
Coover LR
J Nucl Med; 1999 Mar; 40(3):505. PubMed ID: 10086718
[No Abstract] [Full Text] [Related]
12. Development of Graves' hyperthyroidism after radioiodine treatment for a toxic nodule: is the hyperthyroidism always triggered by 1311 therapy?
Niepomniszcze H; Pitoia F; Goodall C; Manavela M; Bruno OD
Thyroid; 2001 Oct; 11(10):991. PubMed ID: 11716050
[No Abstract] [Full Text] [Related]
13. Thyroid function in patients with Graves' disease long after 131I therapy.
Inoue K; Okamura K; Shiroozu A; Nakashima T; Yoshinari M; Omae T; Nishitani H
Fukuoka Igaku Zasshi; 1980 Jul; 71(7):408-16. PubMed ID: 6894288
[No Abstract] [Full Text] [Related]
14. Outcome of radioiodine-131 therapy in hyperfunctioning thyroid nodules: a 20 years' retrospective study.
Ceccarelli C; Bencivelli W; Vitti P; Grasso L; Pinchera A
Clin Endocrinol (Oxf); 2005 Mar; 62(3):331-5. PubMed ID: 15730415
[TBL] [Abstract][Full Text] [Related]
15. [Effect of iodine application during radioiodine therapy in patients with impending therapy failure].
Urbannek V; Schmidt M; Moka D; Hillger HW; Voth E; Wellner U; Schicha H
Nuklearmedizin; 2000; 39(4):108-12. PubMed ID: 10919161
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of the cytokines IL-1beta, IL-6 and ICAM-1 after 131I-treatment of Graves' disease and nodular goiter.
Nygaard B; Jarløv AE; Kristensen LO; Faber J
Horm Metab Res; 2000 Jul; 32(7):283-7. PubMed ID: 10965935
[TBL] [Abstract][Full Text] [Related]
17. A simple and accurate dosimetry protocol to estimate activity for hyperthyroidism treatment.
Skanjeti A; Miranti A; Delgado Yabar GM; Bianciotto D; Trevisiol E; Stasi M; Podio V
Nucl Med Rev Cent East Eur; 2015; 18(1):13-8. PubMed ID: 25633511
[TBL] [Abstract][Full Text] [Related]
18. Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter.
Antonelli A; Rotondi M; Fallahi P; Grosso M; Boni G; Ferrari SM; Romagnani P; Serio M; Mariani G; Ferrannini E
J Clin Endocrinol Metab; 2007 Apr; 92(4):1485-90. PubMed ID: 17244787
[TBL] [Abstract][Full Text] [Related]
19. Unresponsiveness to thyrotropin-releasing hormone (TRH) in treated Graves' hyperthyroidism and in euthyroid Graves' disease.
Clifton-Bligh P; Silverstein GE; Burke G
J Clin Endocrinol Metab; 1974 Apr; 38(4):531-8. PubMed ID: 4206830
[No Abstract] [Full Text] [Related]
20. [Value of the triiodothyronine suppression test with serum T4 and thyroid 131I uptake as indexes in judging the prognosis of Graves' disease].
Luo GC
Zhonghua Yi Xue Za Zhi; 1986 Mar; 66(3):154-6, 189. PubMed ID: 3094869
[No Abstract] [Full Text] [Related]
[Next] [New Search]
